MedKoo product information:

  MG-516 

MG-516 is a novel multi-targeted kinase inhibitor, MG516, that demonstrated potent inhibition of enzymatic activities in vitro and in multiple cell-based assays and in a broad spectrum of xenograft studies.

Current developer:   MethylGene.

The profile of MG516 features the inhibition of a novel spectrum of targets which include members of the Eph receptor family, the Ret receptor tyrosine kinase, Met, and all three vascular endothelial growth factor receptors (VEGFR 1, 2, 3).   MG516 is in advanced preclinical development and ready to commence IND-enabling studies.